SSY Group Limited — Earnings Release 2013

Apr 10, 2013

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [308 x 113] intentionally omitted <==

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

ANNOUNCEMENT OF TURNOVER AND GROSS PROFIT INFORMATION FOR THE THREE MONTHS ENDED 31 MARCH 2013

The Company announces the turnover and gross profit information, which has not been reviewed by its auditors, for the three months ended 31 March 2013.

The board of directors (the “Board”) of Lijun International Pharmaceutical (Holding) Co., Ltd. (the “Company”) announces the financial information of turnover and gross profit of the Company and its subsidiaries (together, the “Group”) for the three months ended 31 March 2013 based on its management accounts which have not been reviewed by the auditors.

Turnover of the Group, which has not been reviewed by the auditors, for the three months ended 31 March 2013 increased by 16.7% as compared with the same period of 2012 to HK$705 million, with gross profit margin of 44.1% (for the three months ended 31 March 2012: 42.0%) and in particular:

• Turnover of Intravenous infusion solution business segment for the first three months in 2013 increased by approximately 32.7% as compared with the same period of 2012 to HK$398 million, with gross profit margin of 45.0% (for the three months ended 31 March 2012: 41.8%). Among which, sales of Non-PVC Soft Bag infusion solution was HK$179 million, representing 49.4% of the sales of intravenous infusion solution and an increase of 51.2% as compared with the same period of 2012; sales of PP Plastic Bottle infusion solution was HK$122 million, representing 33.5% of the sales of intravenous infusion solution and an increase of 23.4% as compared with the same period of 2012; and

— 1 —

• Turnover of Antibiotics finished medicines business segment and Non-antibiotics finished medicines business segment for the first three months in 2013 increased by approximately 3.7% to HK$178 million and decreased by approximately 2.7% to HK$129 million respectively as compared with the same period of 2012, with the aggregated gross profit margin of 42.9% (for the three months ended 31 March 2012: 42.3%); among which, sales of Lijunsha amounted to HK$93.12 million, represented an increase of 4.7% as compared with the same period of 2012; sales of Paiqi amounted to HK$44.94 million, represented an increase of 16.5% as compared with the same period of 2012; sales of Dobesilate amounted to HK$15.83 million, represented a decrease of 31.8% as compared with the same period of 2012; sales of Lixiding amounted to HK$10.35 million, represented an increase of 13.4% as compared with the same period of 2012.

In terms of business segments analysis, Intravenous infusion solution, Antibiotics finished medicines and Non-antibiotics finished medicines accounted for approximately 56.4%, 25.2% and 18.4% respectively of the total turnover of the Group, which has not been reviewed by the auditors, for the first three months in 2013 (for the three months ended 31 March 2012: 49.6%, 28.4% and 22.0% respectively).

Shareholders and potential investors of the Company are advised to exercise caution in dealing in the shares of the Company.

On behalf of the Board Chow Hing Yeung Company Secretary

Hong Kong, 10 April 2013

As at the date of this announcement, the Board comprises Mr. Wu Qin, Mr. Qu Jiguang, Mr. Xie Yunfeng, Mr. Wang Xianjun and Mr. Duan Wei as executive Directors, and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.

— 2 —